31 January 2022 – DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million.
Read MoreSee the following link for a video from Matt Lipscomb, CEO, discussing the latest Series B fundraising.
Read More2 December 2021 – DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.
Read MoreDMC Biotechnologies has completed downstream processing for its first product, the amino acid L-alanine. Processing was done at EW Biotech in Leuna, Germany, following the successful demonstration of commercial scale fermentation at the same site in March.
Read MoreDMC Biotechnologies has successfully produced its lead product, L-alanine at pilot scale. Commercial key performance metrics were achieved and performance from the bench scale was also demonstrated at 3m3 scale fermentation and for each of the downstream purification unit operations. The robustness of DMC’s Dynamic Metabolic Control technology to the process environment was also validated.
Read More